CNBCBiogen's stock rises 3% after company releases new data on late-stage Alzheimer's drugDec 5, 2019more_vert
STATAducanumab: the beginning of the end of Alzheimer's disease?Dec 6, 2019Jason KarlawishBy Jason Karlawishmore_vert